Sintilimab — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase4	Phase 4	152	86	42	309	—	—	Oct 19, 2016
Hodgkin Lymphoma	Phase4	Phase 4	2	1	0	2	—	—	Jul 1, 2021
Malignant Liver Neoplasm	Phase3	Phase 3	25	15	12	54	—	—	Feb 11, 2019
Malignant Lung Neoplasm	Phase3	Phase 3	20	12	4	47	—

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR Mutation1
Cisplatin + Pemetrexed

Clinical trials

Trials with this intervention (317)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 301–317 of 317 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04263870	Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction(CTSCAPOXSEA)	unknown	Phase 2	36	Sichuan UniversityOTHER	1	Feb 11, 2020	clinicaltrials
NCT04065282	The Purpose of This Study is to Evaluate the Efficacy and Safety of Sintilimab in Combination With Xelox as Neoadjuvant Therapy for Patients With Resectable Locally Advanced Gastric or Gastroesophageal Adenocarcinoma.